The strong operational beat and raised guidance reinforce Indivior's standalone growth trajectory, while the Supernus merger adds diversification and synergy upside. Traders should watch for merger closing milestones (Q4 2026) and potential regulatory/stockholder approvals; special dividend announcement may attract arbitrage activity.
Price Chart
Executive Summary
Indivior reported record Q2 2026 results with total net revenue of $343M (up 14% YoY), record SUBLOCADE net revenue of $253M (up 21% YoY), record GAAP net income of $122M, and record adjusted EBITDA of $186M (up 111% YoY). The company raised full-year 2026 guidance across all key metrics and reaffirmed its proposed all-stock merger with Supernus (exchange ratio 1.5401), expected to close in Q4 2026, creating a diversified CNS leader with at least $125M in annual cost synergies and a $1B special dividend for Indivior shareholders.
Key Financial Metrics
Key Facts
- Q2 2026 total net revenue $343M, up 14% YoY from $302M
- Record quarterly SUBLOCADE net revenue $253M, up 21% YoY
- Record GAAP net income $122M ($0.98 diluted EPS) vs $18M ($0.14) YoY
- Record adjusted EBITDA $186M, up 111% YoY from $88M
- Raised FY 2026 guidance: total net revenue to $1,295M-$1,365M (from $1,215M-$1,285M), SUBLOCADE to $1,010M-$1,050M, adjusted EBITDA to $700M-$740M
- Repurchased ~4.7M shares for $175M in Q2; YTD $300M repurchases
- Announced definitive all-stock merger with Supernus at 1.5401 exchange ratio, expected Q4 2026 close
- Pro forma combined company to have ~$2.2B revenue and at least $125M annual cost synergies
- $1B special dividend to pre-closing Indivior shareholders
Financial Impact
Q2 revenue beat with 14% YoY growth; guidance raised by ~$80M at midpoint for total revenue and ~$80M for adjusted EBITDA; merger creates $125M+ annual synergies
Risk Factors
- Merger requires stockholder and regulatory approvals — risk of delay or failure
- Integration risk with Supernus; synergy realization may be slower than expected
- Concentration on SUBLOCADE still exists post-merger despite diversification
- Potential FTC/antitrust review given combined CNS market position
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001193125-26-329521 |
| Document: 0001193125-26-329521-index-headers.html | 0001193125-26-329521 |
| Document: 0001193125-26-329521-index.html | 0001193125-26-329521 |
| Document: 0001193125-26-329521.txt | 0001193125-26-329521 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | EFFECT | $34.47 $35.53 | ▲ +3.08% | ▲ +2.97% | $35.71 (+3.60%) |
Aug 28, 2026 4w ago | S-4 | $34.93 $34.32 | ▼ −1.75% | ▼ −1.60% | $35.71 (+2.23%) |
Aug 3, 2026 8w ago | 425 / 8-K | $37.37 $38.47 | ▲ +2.94% | ▲ +0.92% | $35.71 (−4.44%) |
Aug 3, 2026 8w ago | 425 | $37.37 $38.47 | ▲ +2.94% | ▲ +0.92% | $35.71 (−4.44%) |
Aug 3, 2026 8w ago | 8-K | $37.37 $38.47 | ▲ +2.94% | ▲ +0.92% | $35.71 (−4.44%) |
Aug 3, 2026 8w ago | 425 / 8-K | $37.37 $38.47 | ▲ +2.94% | ▲ +0.92% | $35.71 (−4.44%) |
Jul 23, 2026 10w ago | Press Release | $40.51 $40.22 | ▼ −0.72% | ▼ −1.19% | $35.71 (−11.85%) |
Jun 12, 2026 16w ago | Insider Cluster | $38.40 $38.32 | ▼ −0.21% | ▲ +1.17% | $35.71 (−7.01%) |
May 15, 2026 20w ago | 8-K | $36.54 $37.81 | ▲ +3.48% | ▲ +1.86% | $35.71 (−2.27%) |
May 4, 2026 21w ago | 8-K | $38.98 $38.84 | ▼ −0.36% | ▼ −3.30% | $35.71 (−8.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access